For the quarter ending 2025-09-30, ENSCW made $493,104 in revenue. -$3,729,128 in net income. Net profit margin of -756.26%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Federal grants | 493,104 | 1,371,438 | ||
| Research and development | 2,954,909 | 1,923,430 | ||
| General and administrative | 1,279,290 | 1,198,523 | ||
| Total operating expenses | 4,234,199 | 3,121,953 | ||
| Income (loss) from operations | -3,741,095 | -1,750,515 | ||
| Change in fair value of liability classified warrants | 998 | -853 | ||
| Interest expense, net | 6,369 | 3,160 | ||
| Other income and expense, net | 17,338 | 21,011 | ||
| Total other income (expense), net | 11,967 | 16,998 | ||
| Net income (loss) | -3,729,128 | -1,733,517 | ||
| Deemed dividend related to warrants down round provision | - | 0 | ||
| Net loss attributable to noncontrolling interests | - | -166 | ||
| Net income (loss) attributable to common stockholders | -3,729,128 | -1,733,351 | ||
| Net income (loss) per share attributable to common stockholders, basic | -1.29 | -0.79 | ||
| Net income (loss) per share attributable to common stockholders, diluted | -1.29 | -0.79 | ||
| Weighted average common shares outstanding, basic | 2,886,059 | 2,202,299 | ||
| Weighted average common shares outstanding, diluted | 2,886,059 | 2,202,299 | ||
Ensysce Biosciences, Inc. (ENSCW)
Ensysce Biosciences, Inc. (ENSCW)